This morning Amgen (NASDAQ:AMGN) announced findings from a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer. In this study of more than 1,400 men, denosumab treatment produced statistically significantly greater increases in bone mineral density (BMD) at the [...]
Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they described as a “powerhouse” that drives runaway cell growth. In an article that is being published as an advanced online publication by the journal Nature, the researchers said the growth-stimulating molecule [...]
Prostate cancer, a very prevalent condition, is diagnosed in more than 220,000 men each year in this country, but fewer than 40,000 of those men die of the disease. That’s because prostate cancer often is a slow-growing cancer that does not cause symptoms. Many men can live out their entire lives with prostate cancer without [...]
A recent review of the literature has found that hormone deprivation therapy, a commonly used treatment for prostate cancer, may have subtle adverse effects on cognition in patients–such as in the ability to recall and concentrate. Published in the September 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study [...]
Prostate cancer patients receiving hormone deprivation therapy may experience cognitive decline later in life. A team of researchers from Memorial Sloan-Kettering Cancer Center in New York City analysed 19 small studies examining hormone deprivation therapy, also known as androgen deprivation therapy (ADT). These researches include both animal and human trials. Researchers found that from 47% [...]
A report published in the August 5, 2008 issue of Annals of Internal Medicine says that the U.S. Preventive Services Task Force (USPSTF) has played down the benefits of prostate cancer screening for men above the age of 75. According to the report, the U.S. Preventive Services Task Force is updating its 2002 report on [...]
UC Davis Cancer Center physicians today released results of research showing that Vietnam War veterans exposed to Agent Orange have greatly increased risks of prostate cancer and even greater risks of getting the most aggressive form of the disease as compared to those who were not exposed. The findings, which appear online now and will [...]
Just four days ago, in response to an NBC News story in which reporter George Lewis recommended that all men over age 50 get annual prostate exams including the PSA blood test, I cited the statement of the U.S. Preventive Services Task Force to show that Lewis’ advice was not based in evidence: “The USPSTF [...]
Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they described as a “powerhouse” that drives runaway cell growth. In an article that is being published as an advanced online publication by the journal Nature, the researchers said the growth-stimulating molecule [...]
Men age 75 and older should not be screened for prostate cancer, and younger men should discuss the benefits and harms of the prostate-specific antigen (PSA) test with their clinicians before being tested, according to a new recommendation from the U.S. Preventive Services Task Force. The recommendation and accompanying evidence summary appear in the August [...]
